What it's for (Indications)
- Nicorandil is indicated for the symptomatic treatment of stable angina pectoris in adult patients who are inadequately controlled by, or are intolerant to, first-line anti-anginal therapies.
- It is utilized to reduce the frequency and severity of anginal attacks and improve exercise tolerance.
- Nicorandil can be used as monotherapy or in combination with other anti-anginal agents.
- Its use should be considered within the context of a comprehensive management strategy for coronary artery disease, including lifestyle modifications and other pharmacotherapies as appropriate.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The typical starting dose of nicorandil is 5 mg administered orally twice daily. This dosage may be gradually increased based on individual patient response and tolerability, up to a usual maintenance dose of 10 mg twice daily. In some cases, and under strict medical supervision, the dose may be further increased to a maximum of 20 mg twice daily. Dose adjustments should be made cautiously, particularly in elderly patients or those with renal impairment, due to potential for increased sensitivity to its vasodilatory effects. It is important to adhere strictly to the prescribed dosage regimen to minimize adverse effects while optimizing therapeutic outcomes. |
Safety & Warnings
Common Side Effects
- Common side effects associated with nicorandil include headache, which is often transient and tends to diminish with continued treatment, dizziness, flushing, and nausea or vomiting.
- Less common but notable adverse effects include hypotension, palpitations, and generalized weakness.
- More serious, albeit rare, adverse reactions involve various forms of ulceration: gastrointestinal ulcers (including colonic, small intestinal, and aphthous ulcers), cutaneous ulcers, ocular ulcers (e.
- g.
- , corneal, conjunctival), and genital ulcers.
- Other serious adverse events may include angioedema, liver dysfunction, and pancreatitis.
- Patients should be advised to report any persistent or severe adverse effects to their healthcare provider promptly.
Serious Warnings
- Black Box Warning: Serious Warnings: Nicorandil is associated with a significant risk of severe and potentially life-threatening ulcerations, which can manifest in various locations throughout the body. These include extensive gastrointestinal ulcers (e.g., colonic, small intestinal, aphthous, peptic ulcers), cutaneous ulcers, ocular ulcers (e.g., corneal, conjunctival), and genitourinary ulcers. These ulcerations may be protracted, intractable, and can lead to serious complications such as perforation, hemorrhage, or fistula formation, often necessitating surgical intervention and prolonged hospitalization. Patients experiencing new onset or worsening gastrointestinal symptoms, or any unexplained ulceration, should be promptly evaluated, and nicorandil discontinuation considered if a causal link is suspected. Furthermore, concomitant use of nicorandil with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil, vardenafil) or soluble guanylate cyclase (sGC) stimulators (e.g., riociguat) is strictly contraindicated due to the high risk of profound, sudden, and potentially fatal hypotension. Patients must be thoroughly educated about these critical drug interactions and explicitly advised against concurrent use of these medications.
- Patients should be cautioned against the risk of hypotension, particularly at the initiation of therapy or during dose escalation.
- Nicorandil should be used with extreme caution in patients with heart failure, severe left ventricular dysfunction, or existing hypovolaemia.
- Caution is also advised in patients with glaucoma, as nicorandil may increase intraocular pressure.
- Due to its nitrate-like properties, concurrent use with other vasodilators or medications that can lower blood pressure should be carefully monitored.
- Alcohol consumption during nicorandil therapy may potentiate its hypotensive effects.
- Regular monitoring for the development of ulcerations, particularly gastrointestinal, ocular, or skin lesions, is crucial, and nicorandil should be discontinued if severe or intractable ulcers occur.
How it Works (Mechanism of Action)
Nicorandil exerts its therapeutic effects through a dual mechanism of action, acting as both an ATP-sensitive potassium (K_ATP) channel opener and a nitrate-like compound. As a K_ATP channel opener, it hyperpolarizes the vascular smooth muscle cells by increasing potassium efflux, leading to relaxation and vasodilation of both arterial and venous vessels. This reduces both preload and afterload, decreasing myocardial oxygen demand. Additionally, nicorandil possesses a nitric oxide donor property, stimulating guanylate cyclase and increasing intracellular cyclic guanosine monophosphate (cGMP) levels. This leads to further vasodilation, particularly in the coronary arteries, thereby improving coronary blood flow and oxygen supply to the myocardium. The combined effect results in reduced anginal symptoms and improved exercise tolerance.
Commercial Brands (Alternatives)
No other brands found for this formula.